Delving into the Latest Updates on Sodium Tetradecyl Sulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

7-Ethyl-2-methyl-4-undecanol sulfate sodium salt, 7-ethyl-2-methyl-4-undecanolsulfate, sodium salt, Sodium 2-methyl-7-ethylundecanol-4-sulfate

+ [13]

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Peptic UlcerVaricose Veins

Originator Organization

Elkins-Sinn, Inc.

Active Organization-

Inactive Organization

Elkins-Sinn, Inc.

License Organization-

Drug Highest PhaseWithdrawn

First Approval Date

United States (13 Aug 1946),

Peptic UlcerVaricose Veins

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC14H30NaO4S

InChIKeyZNVVFVQLSXWPEV-UHFFFAOYSA-N

CAS Registry139-88-8

主要目的：评价上药第一生化生产的仿制制剂十四烷基硫酸钠（STS）注射液在中国下肢浅表静脉曲张患者中的药代动力学（PK）特征。次要目的： 1)评估STD Pharmaceutical Products Limited生产的参比制剂Fibrovein®在中国下肢浅表静脉曲张患者中的PK特征。 2)评估仿制制剂和参比制剂在中国下肢浅表静脉曲张患者中的安全性。 3)比较仿制制剂和参比制剂的PK特征。

[Translation]

Primary Objective: To evaluate the pharmacokinetic (PK) characteristics of the generic sodium tetradecyl sulfate (STS) injection produced by Shanghai First Biochemical in Chinese patients with superficial varicose veins of the lower extremities. Secondary Objectives: 1) To evaluate the PK characteristics of the reference product Fibrovein® produced by STD Pharmaceutical Products Limited in Chinese patients with superficial varicose veins of the lower extremities. 2) To evaluate the safety of the generic and reference products in Chinese patients with superficial varicose veins of the lower extremities. 3) To compare the PK characteristics of the generic and reference products.

Start Date26 Jun 2025

Sponsor / Collaborator

SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.

ChiCTR2500108351

/ RecruitingPhase 1IIT

Endoscopic banding combined with intrabulbar sclerosis ligation was used in a clinical research to treat esophagogastric variceal bleeding in liver cirrhosis and portal hypertension

Start Date20 Aug 2024

Sponsor / Collaborator

China-Japan Union Hospital of Jilin University

CTRI/2023/12/060776

/ Not yet recruitingPhase 4IIT

Evaluation of foam sclerotherapy with sodium tetradecyl sulphate in periorbital dermoid cysts - NIL

Start Date26 Dec 2023

Sponsor / Collaborator-

100 Clinical Results associated with Sodium Tetradecyl Sulfate

Login to view more data

100 Translational Medicine associated with Sodium Tetradecyl Sulfate

Login to view more data

100 Patents (Medical) associated with Sodium Tetradecyl Sulfate

Login to view more data

495

Literatures (Medical) associated with Sodium Tetradecyl Sulfate

01 Feb 2026·OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Role of Sclerotherapy in Treating Oral Vascular Malformations in Hereditary Hemorrhagic Telangiectasia

Article

Author: Prosser, Aaron ; Joshi, Advay ; Adelman, Avraham E. ; Ataya, Ali ; Mathavan, Akshay ; Gallo, Kimberly ; Mathavan, Akash ; Justice, Jeb

Abstract:

Oral telangiectasias in hereditary hemorrhagic telangiectasia (HHT) can significantly impair quality of life. While sclerotherapy is an established treatment for HHT‐related epistaxis, it is rarely used for oral telangiectasias. We retrospectively reviewed HHT patients who underwent oral sclerotherapy between 2021 and 2024 at a tertiary academic center. Eleven patients (64% female, mean age 61.3 years, 82% ACVRL1 genotype) underwent sclerotherapy using a 1:4 mixture of 3% sodium tetradecyl sulfate and air. Lesions treated included the lip (36%), tongue (36%), hard palate (18%), and gingiva (9%). Presenting symptoms included oral bleeding with eating and dietary limitations. Adverse effects included transient lip swelling (n = 2) and tongue burning (n = 1). At an average follow‐up of 6 months, 10/11 patients with follow‐up data had complete symptomatic and clinical resolution. Our findings suggest that oral sclerotherapy is a safe, effective, and minimally invasive treatment for HHT‐related oral bleeding that clinicians should consider.

15 Dec 2025·Cureus Journal of Medical Science

Short-Term Outcome of Foam Sclerotherapy With Sodium Tetradecyl Sulphate for the Treatment of Venous Malformation in Dhaka, Bangladesh: A Single-Centre Experience

Article

Author: Khan, Md Arif Uddin ; Aziz, Nur Mohammod Sayed Bin ; Akter, Afroza ; Khan, Masrur Akbar ; Rahman, Md Mezbahur

BACKGROUND:

Treatment of venous malformations is challenging for physicians. Previously, surgery was regarded as the only treatment option. Recently, sclerotherapy has been proven to be a low-cost, effective, and convenient substitute with minimal discomfort and blood loss. It doesn't require local anaesthesia or postoperative care, allowing for immediate return to daily activities. This paper objectives to account for a single-centre experience with the use of foam sclerotherapy using sodium tetradecyl sulfate (STS) for venous malformations and to present the short-term clinical outcome, including symptom improvement, safety, and size reduction.

METHODS:

A prospective study was conducted in the Vascular Surgery Department, Bangladesh Medical University (BMU) between July 2021 to December 2021. We selected 21 patients with low-flow venous malformations confirmed by magnetic resonance imaging (MRI) and duplex ultrasonography. All the patients received STS foam sclerotherapy after clinical and radiological assessment. Each lesion received multiple sessions. A follow-up was done for radiological and clinical improvement of the lesions.

RESULT:

The median age of the participant was 17 (12, 29) years. Around half of the participants (n=9; 42.9%) were from the 11-20 years of age group, with almost a similar sex distribution. Both upper and lower limbs were the most commonly affected regions (n=9, 42.9%; in each limb). Swelling was observed in all participants, and 16 presented with pain. After sclerotherapy, swelling and pain decreased in all participants (100%). A total of nine (42.9%) participants required three sessions of sclerotherapy, followed by eight (37.2%) patients who required four sessions. Several sessions of 3-4 ml of STS were required by 38.1% (n=8) participants, followed by 33% (n=7) requiring 2-2.9 ml/session. All participants experienced pain following sclerotherapy. While 14 (66.7%) of the participants obtained ≥50% response, among them five (23.8%) were completely reduced. The other seven (33.3%) cases resulted in <50% resolution.

CONCLUSION:

Overall, STS sclerotherapy is an effective treatment procedure for low-flow venous malformations with a low complication rate. Moreover, it offers a convenient and cost-effective outpatient-based treatment option to most patients with uncomplicated venous malformations.

30 Oct 2025·NEPHROLOGY DIALYSIS TRANSPLANTATION

Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts

Article

Author: Kline, Timothy ; Liestikow, Kathleen ; Hogan, Marie C ; Kseibi, Firas ; Helland, Ryan ; Bugazia, Seif ; Vaughan, Lisa ; Martin, William P ; Howe, Cassie ; Gregory, Adriana ; Bendel, Emily ; Neidert, Newton ; Torres, Vicente E

ABSTRACT:

Background:

This medical center migrated from alcohol to sotradecol foam sclerotherapy (SFS) because of perceived improved efficacy in managing symptomatic kidney and liver cysts. We report technical aspects, change in short- and long-term cyst volumes, patient-reported outcomes, safety and applications of the technique.

Methods:

In this retrospective observational study, cases from January 2017 to December 2021 had TKCV/TLCV (per Targeted Kidney or Liver or Cyst analysis) segmented using a deep-learning algorithm and cyst segmentation software (pre-, post-procedure and longitudinally). TKCV/TLCV % change were evaluated using the one-sample Wilcoxon signed rank test. For analyses involving changes in cyst volumes, the median % change in cyst volume per patient was assessed. Longitudinal changes in cyst volumes were assessed using linear mixed models. Changes in quality of life (QOL) [Linear Analog Self-Assessment (LASA), Polycystic Liver Disease Quality of life Questionnaire (PLD-Q) and 12-item short-form (SF12)] were also assessed.

Results:

There were 102 SFS sessions (38 kidney, 58 liver, 6 combined liver/kidney cysts) performed on 77 unique individuals included for analysis. Median [interquartile range (IQR)] % reductions in TKCV were –92.0% (IQR –98.2%, –82.7%, P < .001) and for TLCV were –83.1% (IQR –93.5%, –52.9%, P < .001). Among patients with multiple kidney procedures (n = 7), median % reduction in TKCV was –94.3% (IQR –96.6%, –92.4%, P = .023). For patients with multiple liver procedures (n = 11), median % reduction in TLCV was –63.3% (IQR –85.2%, –28.3%, P = .004). Results were similar among the four patients undergoing multi-stage procedures (n = 1 kidney, n = 3 liver). When measured longitudinally, both liver and kidney cyst volumes declined to levels near 0 mL by 1 year follow-up and remained stable several years later. LASA physical domain and PLD-Q QOL scores improved post-SFS procedure.

Conclusion:

SFS led to substantial long-term reductions in TKCV/TLCV and improved QOL. SFS can augment cyst volume reduction in addition to tolvaptan (kidney cysts) and octreotide (liver cysts). In some individuals with large symptomatic cysts, multiple SFS procedures were safe and effective in reducing TLCV/TKCV and improving symptoms.

100 Deals associated with Sodium Tetradecyl Sulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06882	Sodium Tetradecyl Sulfate	C05BB04	DB00464

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Peptic Ulcer	United States	Elkins-Sinn, Inc.	13 Aug 1946
Varicose Veins	United States	Elkins-Sinn, Inc.	13 Aug 1946

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02557542 (OSVeC, CTgov)	Not Applicable	Varicose Veins	3	Endovenous laser ablation+Sodium Tetradecyl+Polidocanol (One Stop Vein Clinic)	jwfkivmqah(yvxvkherho) = pswcmbjxmi silwmjrndb (lkfdozlrqx, smxhprasqe - jpfgqurcqd) View more	-	16 May 2025
				Endovenous laser ablation+Sodium Tetradecyl+Polidocanol (Normal Care Pathway)	jwfkivmqah(yvxvkherho) = mpelvemhyi silwmjrndb (lkfdozlrqx, llecscqvlq - zbxfexnlat) View more
NCT03311269 (VICARES, CTgov)	Phase 2	Venous Insufficiency	19	ClariVein RES+Sodium Tetradecyl Sulfate 1% Injection (ClariVein RES 1% Injection)	rluwtyvrky(qafngowbwb) = ccfvexgulu dtcvxwzdfz (lwoczdqrcl, 3.00) View more	-	02 Mar 2022
				ClariVein RES+Sodium Tetradecyl Sulfate 3% Injection (ClariVein RES 3% Injection)	rluwtyvrky(qafngowbwb) = dcsisbpbop dtcvxwzdfz (lwoczdqrcl, 1.87) View more
NCT03363633 (Dillavou, CTgov)	Not Applicable	Vein disorder	12	sodium tetradecyl sulfate	xcpcevuuyd(qvjvhfslsl) = guyxkqcsqd lgugokplps (ijmuuymiyf, tklwtulsnj - fimnisrsbh) View more	-	23 Feb 2018
SIOPEL 6 (AACR2016)	Phase 3	Hepatoblastoma	37	Cisplatin + Sodium Thiosulphate (STS)	tdgxelwzsr(yktagzimaj) = cpqbeqzqzc tapiprzmxf (urdvicsoga )	-	15 Jul 2016
				Cisplatin alone	tdgxelwzsr(yktagzimaj) = tnwddhgkca tapiprzmxf (urdvicsoga )